These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10810398)

  • 21. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
    Harpole DH; Moore MB; Herndon JE; Aloia T; D'Amico TA; Sporn T; Parr A; Linoila I; Allegra C
    Clin Cancer Res; 2001 Mar; 7(3):562-9. PubMed ID: 11297249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
    Venesmaa P
    Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.
    Kountourakis P; Psyrri A; Scorilas A; Markakis S; Kowalski D; Camp RL; Diamandis EP; Dimopoulos MA
    Thromb Haemost; 2009 Mar; 101(3):541-6. PubMed ID: 19277417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis.
    Masciullo V; Ferrandina G; Pucci B; Fanfani F; Lovergine S; Palazzo J; Zannoni G; Mancuso S; Scambia G; Giordano A
    Clin Cancer Res; 2000 Dec; 6(12):4816-22. PubMed ID: 11156240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.
    Chua DT; Nicholls JM; Sham JS; Au GK
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):11-20. PubMed ID: 15093894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
    Zhao XD; Zhang Y; He SR; Yang L
    Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
    Khouja MH; Baekelandt M; Nesland JM; Holm R
    Int J Gynecol Pathol; 2007 Oct; 26(4):418-25. PubMed ID: 17885492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
    Lund B; Williamson P
    Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.